Aspire Biopharma Holdings, Inc.

For the period ended Dec 31, 2025. Filed Mar 30, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 30, 2026

ASBP$8.51+5.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations

	For the Years Ended December 31,
2025 · 2024
Net revenue	$6,202	$	-
Cost of revenue	6,318		-
Gross margin	(116)		-
OPERATING EXPENSES
General and administrative (including stock-based compensation of $14.1 million and $0, respectively)	17,637,432		940,421
Research and development	923,914		144,356
Sales and marketing	789,829		126,094
Total operating expenses	19,351,175		1,210,871
Loss from operations	(19,351,291)		(1,210,871)
Other income (expense):
Interest expense	(8,531,275)		(97,988)
Change in fair value of liabilities	3,860,889		-
Initial recognition of forward purchase liability	(95,062)		-
Loss on extinguishment of debt	(364,109)		-
Total other expense, net	(5,129,557)		(97,988)
Loss before provision for income taxes	(24,480,848)		(1,308,859)
Income tax expense	-		(1,013)
Net loss	$(24,480,848)		$(1,309,872)
Weighted average shares outstanding of Common Stock	1,494,956		689,913
Basic and diluted net loss per share of Common Stock	$(16.38)		$(1.90)

The Company’s weighted average shares outstanding of common stock for the years ended December 31, 2025 and 2024 have been retroactively restated for the reverse stock split as described in Note 3 of the accompanying notes, which are an integral part of these consolidated financial statements.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.